aplastic anemia | Page 78 | Aplastic Anemia & MDS International Foundation Return to top.

aplastic anemia

Immune markers of disease severity and treatment response in pediatric acquired aplastic anemia

Author(s): 
Sutton KS, Shereck EB, Nemecek ER, Kurre P
Primary Author: 
Sutton KS
Journal Title: 
Pediatr Blood Cancer
Original Publication Date: 
Jul 2012

BACKGROUND:

To investigate the immune status among pediatric patients with aplastic anemia (AA) and explore PNH-status, T-regulatory and NK-cell frequency as potential markers of clinical response.

METHODS:
Data were retrospectively analyzed from twenty-six patients diagnosed with AA. PNH populations, T- and NK-subsets were determined via flow cytometry.

RESULTS:

Bone Marrow Disease(s): 

Michael Keng, MD

Keng, Michael
Assistant Professor, Division of Hematology/Oncology
University of Virginia Cancer Center

Dr. Michael Keng holds a clinical faculty appointment in Medicine in the Division of Hematology/Oncology at UVA Cancer Center. He practices at the Emily Couric Clinical Cancer Center in Charlottesville and serves as an inpatient hematologist at UVA Hospital.

Online Profile: 
Online Profile Here

Alternative donor HSCT in refractory acquired aplastic anemia - Prevention of graft rejection and graft versus host disease by immunoablative conditioning and graft manipulation

Author(s): 
Urban C, Benesch M, Sovinz P, Sipurzynski S, Lackner H, Müller E, Schwinger W
Primary Author: 
Urban C
Journal Title: 
Pediatr Transplant
Original Publication Date: 
Mar 2012

Urban C, Benesch M, Sovinz P, Sipurzynski S, Lackner H, Müller E, Schwinger W. Alternative donor HSCT in

Bone Marrow Disease(s): 

Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party

Author(s): 
Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, Killick SB, Warren AJ, Foukaneli T, Aljurf M, Al-Zahrani HA, Schafhausen P, Roth A, Franzke A, Brummendorf TH, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute MO,
Primary Author: 
Marsh JC
Journal Title: 
Blood
Original Publication Date: 
Apr 2012

Rabbit

Bone Marrow Disease(s): 

Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels

Author(s): 
Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer ES, Gersten ID, Carter SL, Horowitz MM, Nakamura R, Pulsipher MA, Difronzo NL, Confer DL, Eapen M, Anderlini P
Primary Author: 
Tolar J
Journal Title: 
Biol Blood Marrow Transplant
Original Publication Date: 
Apr 2012

Excessive adverse events were encountered in a Phase I/II study of

Bone Marrow Disease(s): 

Cotransplantation of allogeneic mesenchymal and hematopoietic stem cells in children with aplastic anemia

Author(s): 
Wang H, Yan H, Wang Z, Zhu L, Liu J, Guo Z
Primary Author: 
Wang H
Journal Title: 
Pediatrics
Original Publication Date: 
May 2012

We report here the preliminary results of allogeneic hematopoietic stem cell transplantation with mesenchymal

Bone Marrow Disease(s): 
Share with addtoany.com.